Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys
Open accessPublished version of a preprint
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Establishing how many people have been infected by SARS-CoV-2 remains an urgent priority for controlling the COVID-19 pandemic. Serological tests that identify past infection can be used to estimate cumulative incidence, but the relative accuracy and robustness of various sampling strategies have been unclear. We developed a flexible framework that integrates uncertainty from test characteristics, sample size, and heterogeneity in seroprevalence across subpopulations to compare estimates from sampling schemes. Using the same framework and making the assumption that seropositivity indicates immune protection, we propagated estimates and uncertainty through dynamical models to assess uncertainty in the epidemiological parameters needed to evaluate public health interventions and found that sampling schemes informed by demographics and contact networks outperform uniform sampling. The framework can be adapted to optimize serosurvey design given test characteristics and capacity, population demography, sampling strategy, and modeling approach, and can be tailored to support decision-making around introducing or removing interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mixOmics: An R package for ‘omics feature selection and multiple data integration
Rohart, F., Gautier, B., Singh, A., & Lê Cao, K.-A. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005752 · Cited by 4,056
Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611
Self-citationStringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B. (2021) · Science · doi:10.1126/science.abe6959 · Cited by 775 · cited 2×
“…of the population that has been infected by, and recovered from, the coronavirus causing COVID-19 will be a critical measure to inform policies on a population level, including when and how social distancing interventions can be relaxed, and the prioritization of vaccines ( Bubar et al., 2021 ).”
Self-citationKissler, S. M., Kishore, N., Prabhu, M., Goffman, D., Beilin, Y., Landau, R., Gyamfi-Bannerman, C., Bateman, B. T., Snyder, J., Razavi, A. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18271-5 · Cited by 129 · cited 1×
“There are a number of limitations to this approach that reflect uncertainties in the underlying assumptions of serological responses and the changes in mobility and interactions due to public health efforts ( Kissler et al., 2020b ).”
Self-citationSARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak
Valenti, L., Bergna, A., Pelusi, S., Facciotti, F., Lai, A., Tarkowski, M., Berzuini, A., Caprioli, F., Santoro, L., Baselli, G., et al. (2020) · doi:10.1101/2020.05.11.20098442 · Cited by 88
Research works printed but not linked: 34
- Abrams, 2014, Assessing mumps outbreak risk in highly vaccinated populations using spatial seroprevalence data, American Journal of Epidemiology, 179, 1006, 10.1093/aje/kwu014 · DOI
- Ainslie, 2020, Evidence of initial success for China exiting COVID-19 social distancing policy after achieving containment, Wellcome Open Research, 5, 10.12688/wellcomeopenres.15843.2 · DOI
- Bendavid, 2020, COVID-19 antibody seroprevalence in santa clara county, California, 10.1101/2020.04.14.20062463 · DOI
- Buckee, 2020, Aggregated mobility data could help fight COVID-19, Science, 368, 145, 10.1126/science.abb8021 · DOI · Paper page
- Davies, 2020, Age-dependent effects in the transmission and control of COVID-19 epidemics, Nature Medicine, 26, 1205, 10.1038/s41591-020-0962-9 · DOI · Paper page
- Diggle, 2011, Estimating prevalence using an imperfect test, Epidemiology Research International, 2011, 1, 10.1155/2011/608719 · DOI · Paper page
- Erikstrup, 2021, Estimation of SARS-CoV-2 infection fatality rate by Real-time antibody screening of blood donors, Clinical Infectious Diseases, 72, 249, 10.1093/cid/ciaa849 · DOI · Paper page
- Farrington, 2001, Estimation of the basic reproduction number for infectious diseases from age‐stratified serological survey data, Journal of the Royal Statistical Society: Series C, 50, 251, 10.1111/1467-9876.00233 · DOI · Paper page
- Farrington, 2003, Estimation of effective reproduction numbers for infectious diseases using serological survey data, Biostatistics, 4, 621, 10.1093/biostatistics/4.4.621 · doi:10.1093/biostatistics/4.4.621
- Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, Bhatia S, Boonyasiri A, Cucunubá Z. 2020. Imperial College COVID-19 Response Team. Report 9: Impact of Non-Pharmaceutical Interventions (NPIs) Toreduce COVID-19 Mortality and Healthcare Demand.
- Fontanet, 2020, Cluster of COVID-19 in northern France: a retrospective closed cohort study, 10.1101/2020.04.18.20071134 · DOI
- Gelman, 2020, Bayesian analysis of tests with unknown specificity and sensitivity, 10.1101/2020.05.22.20108944 · DOI
- Hanley, 1983, If nothing Goes wrong, is everything all right? interpreting zero numerators, Jama, 249, 1743, 10.1001/jama.1983.03330370053031 · DOI · Paper page
- Hens, 2012, Modeling Infectious Disease Parameters Based on Serological and Social Contact Data: A Modern Statistical Perspective, 10.1007/978-1-4614-4072-7 · DOI
- Herzog, 2017, Mathematical models used to inform study design or surveillance systems in infectious diseases: a systematic review, BMC Infectious Diseases, 17, 10.1186/s12879-017-2874-y · doi:10.1186/s12879-017-2874-y
- Larremore, 2020, Implications of test characteristics and population seroprevalence on immune passport strategies, Clinical Infectious Diseases, 20, 10.1093/cid/ciaa1019 · DOI
- Larremore D. 2021. covid_serological_sampling. Software Heritage. swh:1:rev:262fb34c19c4bb48bdc74dad1470e4bf8bbe5a69. https://archive.softwareheritage.org/swh:1:dir:8a3850a3d88cef608b5875c9a85e39c87f866153;origin=http://github.com/LarremoreLab/covid_serological_sampling;visit=swh:1:snp:7f1ab5f38e6ee057b48a1f925a0c646ddfaaf403;anchor=swh:1:rev:262fb34c19c4bb48bdc74dad1470e4bf8bbe5a69/.
- Larremore, 2020, Jointly modeling prevalence, sensitivity and specificity for optimal sample allocation, 10.1101/2020.05.23.112649 · DOI
- Little, 1993, Post-Stratification: a modeler's Perspective, Journal of the American Statistical Association, 88, 1001, 10.1080/01621459.1993.10476368 · DOI · Paper page
- Malani, 2020, Seroprevalence of sars-cov-2 in slums and non-slums of Mumbai, India, during June 29-july 19, 2020, 10.1101/2020.08.27.20182741 · DOI
- Mark Newman, 2018, Networks, 10.1093/oso/9780198805090.001.0001 · DOI · Paper page
- Martin, 2018, Births: final data for 2016, National Vital Statistics Reports : From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 67, 1
- Nisar, 2020, Serial population based serosurvey of antibodies to sars-cov-2 in a low and high transmission area of Karachi, pakistan, 10.1101/2020.07.28.20163451 · DOI
- Open COVID-19 Data Working Group, 2020, The effect of human mobility and control measures on the COVID-19 epidemic in China, Science, 368, 493, 10.1126/science.abb4218 · DOI · Paper page
- Prem, 2017, Projecting social contact matrices in 152 countries using contact surveys and demographic data, PLOS Computational Biology, 13, 10.1371/journal.pcbi.1005697 · DOI · Paper page
- Saad-Roy, 2020, Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years, Science, 370, 811, 10.1126/science.abd7343 · DOI · Paper page
- Shaz, 2011, Demographic patterns of blood donors and donations in a large metropolitan area, Journal of the National Medical Association, 103, 351, 10.1016/S0027-9684(15)30316-3 · doi:10.1016/s0027-9684(15)30316-3
- St-Onge, 2019, Efficient sampling of spreading processes on complex networks using a composition and rejection algorithm, Computer Physics Communications, 240, 30, 10.1016/j.cpc.2019.02.008 · DOI
- Sutton, 2020, Universal screening for SARS-CoV-2 in women admitted for delivery, New England Journal of Medicine, 382, 2163, 10.1056/NEJMc2009316 · DOI · Paper page
- Tan, 2020, Viral kinetics and antibody responses in patients with COVID-19, 10.1101/2020.03.24.20042382 · DOI · Paper page
- United Nations. 2019. Department of Economic and Social Affairs, Population Division. World Population Prospects 2019.
- Ward, 2020, Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365000 adults, 10.1101/2020.10.26.20219725 · DOI
- Weitz, 2020, Modeling shield immunity to reduce COVID-19 epidemic spread, Nature Medicine, 26, 849, 10.1038/s41591-020-0895-3 · DOI · Paper page
- Winter, 2018, Revealing measles outbreak risk with a nested immunoglobulin G serosurvey in Madagascar, American Journal of Epidemiology, 187, 2219, 10.1093/aje/kwy114 · DOI
Cited by
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B. (2021) · Science · doi:10.1126/science.abe6959 · Cited by 775
“We demonstrated that there is value in pairing individual-level serological tests with vaccination, even when accounting for the uncertainties in seroprevalence estimates ( 29 ).”
Self-citationKissler, S. M., Kishore, N., Prabhu, M., Goffman, D., Beilin, Y., Landau, R., Gyamfi-Bannerman, C., Bateman, B. T., Snyder, J., Razavi, A. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18271-5 · Cited by 129
Self-citationKleynhans, J., Tempia, S., Wolter, N., von Gottberg, A., Bhiman, J. N., Buys, A., Moyes, J., McMorrow, M. L., Kahn, K., Gómez-Olivé, F. X., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2712.211465 · Cited by 97
“We adjusted seroprevalence estimates for sensitivity and specificity, as previously described (14), on the basis of the manufacturers’ reported 99.”
MethodChibwana, M. G., Jere, K. C., Kamng'ona, R., Mandolo, J., Katunga-Phiri, V., Tembo, D., Mitole, N., Musasa, S., Sichone, S., Lakudzala, A., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16188.1 · Cited by 110
Metadata
- Authors
- Larremore, D. B., Fosdick, B. K., Bubar, K. M., Zhang, S., Kissler, S. M., Metcalf, C. J. E., Buckee, C. O., & Grad, Y. H.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2021-03-05
- Volume
- 10
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W3017144323
- Cited by
- 95
- References
- 7
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (am)
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- Morris-Singer Fund for the Center for Communicable Disease Dynamics
- National Cancer Institute (1U01CA261277-01)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. https://app.cochat.ai/papers/10.7554/elife.64206
- The paper
- Larremore, D. B., Fosdick, B. K., Bubar, K. M., Zhang, S., Kissler, S. M., Metcalf, C. J. E., Buckee, C. O., & Grad, Y. H. (2021). Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. eLife. https://doi.org/10.7554/elife.64206
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.